OncoTherapy Science (4564) Reports Latest Financial Results: Revenue Decreases by 15.2% YoY, Operating Loss of 285 Million Yen

OncoTherapy Science (4564) has released its latest financial results, reporting net sales of 170 million yen, which represents a 15.2% decrease year-on-year compared to the same period of the previous year. On the profit front, the company posted an operating loss of 285 million yen, an ordinary loss of 287 million yen, and a net loss attributable to owners of the parent of 288 million yen. Basic earnings per share (EPS) stood at -0.72 yen.

Examining the financial structure and key indicators, the equity ratio remains relatively high at 87.2%, reflecting a sound financial foundation. However, retained earnings stand at -28.11 billion yen, highlighting the ongoing challenge of addressing accumulated losses over the long term. Furthermore, Return on Equity (ROE) was -12.68% and Return on Assets (ROA) was -11.06%, indicating that profitability improvement remains a key focus. Going forward, market attention will likely center on the progress of core R&D activities and milestones toward monetization.